Cardiome Pharma Corp. (Cardiome) is a research-based biopharmaceutical company. The Company is focused on the discovery, development and commercialization of new therapies. It has one product, BRINAVESS, approved for marketing in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults. The Company's clinical programs are also focused on the treatment of atrial fibrillation, an arrhythmia (or abnormal rhythm) of the upper chambers of the heart. Cardiome also has several pre-clinical projects directed at various therapeutic indications. The Company operates primarily in one business segment with all of its assets located in Canada and operations located in Canada, the United States, Switzerland and the United Kingdom. In March 2012, the Company announced that Merck & Co., Inc. (Merck) discontinued further development of vernakalant (oral).
6190 Agronomy Rd.
VANCOUVER, BC, Canada V6T 1Z3
|Chairman of the Board||Robert Rieder|
|President, Chief Executive Officer, Director||William Hunter|
|Chief Financial Officer||Jennifer Archibald|
|Chief Operating Officer||Sheila Grant|
|Chief Commercial Officer||Karim Lalji|
With TD Waterhouse, you have access to the industry's leading selection of independent research reports from providers such as TDSI, TD Securities, S&P, INK and Argus.
|Shares Out.||12.5M||Book Value||$0.63|
|Annual Dividend Rate||$0.00||Price/Sales (TTM)||66.8|
|Ex-Div Date||1/1/01||P/Cash Flow (TTM)||3.4x|
|Pay Date||1/1/01||Operating Margin||2,307.69%|
*GAAP = prior to non-GAAP analyst adjusted earnings.